Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shelley K. Ballentine is active.

Publication


Featured researches published by Shelley K. Ballentine.


Bioorganic & Medicinal Chemistry Letters | 2012

Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia.

Raul R. Calvo; Sanath K. Meegalla; Daniel J. Parks; William H. Parsons; Shelley K. Ballentine; Mary Lou Lubin; Craig Schneider; Raymond W. Colburn; Christopher M. Flores; Mark R. Player

Thermosensitive transient receptor potential melastatin 8 (TRPM8) antagonists are considered to be potential therapeutic agents for the treatment of cold hypersensitivity. The discovery of a new class of TRPM8 antagonists that shows in vivo efficacy in the rat chronic constriction injury (CCI)-induced model of neuropathic pain is described.


Bioorganic & Medicinal Chemistry Letters | 2012

Design and synthesis of polyethylene glycol-modified biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s

Nalin L. Subasinghe; Ehab Khalil; Jeremy M. Travins; Farah Ali; Shelley K. Ballentine; Heather Rae Hufnagel; Wenxi Pan; Kristi A. Leonard; Roger F. Bone; Richard M. Soll; Carl S. Crysler; Nisha Ninan; Jennifer Kirkpatrick; Michael X. Kolpak; Karen DiLoreto; Stephen H. Eisennagel; Norman D. Huebert; Christopher J. Molloy; Bruce E. Tomczuk; Michael David Gaul

Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS). The utility of biphenylsulfonyl-thiophene-carboxamidine small-molecule C1s inhibitors are limited by their poor in vivo pharmacokinetic properties. Pegylation of a potent analog has provided compounds with good potency and good in vivo pharmacokinetic properties.


Bioorganic & Medicinal Chemistry Letters | 2013

Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors

Carl R. Illig; Carl L. Manthey; Sanath K. Meegalla; Mark J. Wall; Jinsheng Chen; Kenneth J. Wilson; Renee L. Desjarlais; Shelley K. Ballentine; Carsten Schubert; Carl S. Crysler; Yanmin Chen; Christopher J. Molloy; Margery A. Chaikin; Robert R. Donatelli; Edward J. Yurkow; Zhao Zhou; Mark R. Player; Bruce E. Tomczuk

Structure-activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7 nM, FMS cell IC50 6.1 nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats.


Archive | 2007

INHIBITORS OF C-FMS KINASE

Carl R. Illig; Shelley K. Ballentine; Jinsheng Chen; Renee L. Desjarlais; Sanath K. Meegalla; Mark J. Wall; Kenneth J. Wilson


Archive | 2005

Aromatic amides as inhibitors of c-fms kinase

Carl R. Illig; Shelley K. Ballentine; Jinsheng Chen; Sanath K. Meegalla; Jonathan Rudolph; Mark J. Wall; Kenneth J. Wilson; Renee L. Desjarlais; Carl L. Manthey; Christopher M. Flores; Christopher J. Molloy


Archive | 2006

Method of inhibiting flt3 kinase

Shelley K. Ballentine; Christian Andrew Baumann; Jingsheng Chen; Carl R. Illig; Saneth K. Meegalla; M. Jonathan Rudolph; Robert W. Tuman; Mark J. Wall; Kenneth J. Wilson; Dana L. Johnson


Archive | 2009

HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS

Mark R. Player; Daniel J. Parks; William H. Parsons; Sanath K. Meegalla; Carl R. Illig; Shelley K. Ballentine


Archive | 2007

Method of inhibiting C KIT kinase

Carl R. Illig; Shelley K. Ballentine; Jinsheng Chen; Sanath K. Meegalla; M. Jonathan Rudolph; Mark J. Wall; Kenneth J. Wilson; Renee L. Desjarlais; Carl M. Manthey; Christopher J. Molloy


Archive | 2006

Novel thiophene sulfoximines for treating complement-mediated diseases and conditions

Nalin L. Subasinghe; Shelley K. Ballentine; Jeremy M. Travins; Ehab Khalil; Farah Ali; Kristi A. Leonard; Joan M. Gushue; Michael P. Winters; Heather Rae Hufnagel; Maxwell D. Cummings


Archive | 2005

Class of arylamide compounds useful as inhibitors of c-fms kinase

Carl R. Illig; Shelley K. Ballentine; Jinsheng Chen; Sanath K. Meegalla; Jonathan Rudolph; Mark J. Wall; Kenneth J. Wilson; Renee L. Desjarlais; Carl L. Manthey; Christopher M. Flores; Christopher J. Molloy

Collaboration


Dive into the Shelley K. Ballentine's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge